SCHEMBL6443053

SCHEMBL6443053

COc1ccccc1-c1nc(N)nc(OCc2ccccn2)c1C#N

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.60
ADORA1 P30542 6/20 0.60
CHRNA7 P36544 3/20 0.47
SYK P43405 2/20 0.45
AURKB Q96GD4 1/20 0.45
INCENP Q9NQS7 1/20 0.45
MGMT P16455 1/20 0.44
HTT P42858 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
BLM P54132 1/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443184 0.91 ADORA2A (0.56) ADORA2AADORA1CHRNA7HTTKDM4E
SCHEMBL6441414 0.83 MGMT (0.55) ADORA2AADORA1SYKMGMTKDM4E
SCHEMBL5041645 0.83 ADORA1 (0.57) ADORA2AADORA1MGMT
SCHEMBL6443675 0.83 MGMT (0.48) ADORA2AADORA1SYKMGMTKDM4E
SCHEMBL6444027 0.83 ADORA2A (0.54) ADORA2AADORA1CHRNA7HTTKDM4E
SCHEMBL5039926 0.79 ADORA2A (0.52) ADORA2AADORA1MGMTKDM4EALDH1A1
SCHEMBL5044782 0.78 ADORA2A (0.56) ADORA2AADORA1MGMTKDM4EALDH1A1
SCHEMBL5041663 0.78 ADORA2A (0.56) ADORA2AADORA1MGMTKDM4EALDH1A1
SCHEMBL6443183 0.78 MGMT (0.42) ADORA2AADORA1SYKAURKBINCENP
SCHEMBL6443037 0.78 SQOR (0.51) ADORA2AADORA1MGMTBLMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885CHRNA7 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.